Clinical Study Data Request Registered Users, Please Login

Find by:

Study ID:
Medicine:
Phase:

A phase III partially double blind study evaluating the efficacy and safety of 40KD branched pegylated interferon alfa-2a (PEG-IFN, RO0258310) combined with placebo or lamivudine versus lamivudine in HBeAg positive patients with chronic hepatitis B
peg-interferon alpha-2a
WV16240
NCT00048945
chronic hepatitis b
Phase 3
 
January 2014

Powered by ideaPoint, Inc.